SS Innovations Launches Sri Lanka's First Robotic Cardiac Surgery Program

SS Innovations International (NASDAQ: SSII) has expanded its global footprint with the launch of Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo. The program utilizes the company's SSi Mantra 3.0 surgical robotic system, marking a significant milestone in the adoption of robotic-assisted cardiac care in South Asia. The initiative underscores the growing global demand for minimally invasive surgical technologies and positions SS Innovations as a key player in advancing cardiac surgery in emerging markets.

The program commenced with a robotic-assisted left internal mammary artery (LIMA) takedown, performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. This procedure exemplifies the precision and potential of robotic systems in complex cardiac interventions. According to a recent company video describing the program's early activity, Kings Hospital has already completed more than 25 robotic procedures in just three weeks, demonstrating rapid adoption and proficiency with the SSi Mantra system.

The significance of this launch extends beyond Sri Lanka's borders. It signals the broader potential for robotic cardiac surgery to become more accessible in regions where such advanced care was previously unavailable. For SS Innovations, this program serves as a showcase for its technology's capabilities and could catalyze further adoption across Asia and other emerging markets. The company reported 224 cumulative SSi Mantra installations across 12 countries at the end of the second quarter, reflecting its expanding global presence.

Financially, SS Innovations is experiencing strong momentum. Second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528. This surge in procedure volume points to rising utilization of the company's installed base, a critical metric for recurring revenue and long-term growth. As more hospitals adopt the SSi Mantra system and surgeons gain experience, the company is well-positioned to benefit from increasing demand for robotic-assisted surgeries.

The next major corporate milestone for SS Innovations is regulatory expansion. The company is actively pursuing U.S. Food and Drug Administration (FDA) clearance and European CE marking for the SSi Mantra system. Achieving these certifications would open doors to the world's largest healthcare markets, significantly broadening the company's addressable market and competitive stance. Success in these endeavors could accelerate revenue growth and solidify SS Innovations' position as a global leader in surgical robotics.

For investors and industry observers, the launch in Sri Lanka is more than a single hospital milestone; it is a proof point of the SSi Mantra's versatility and effectiveness in a new clinical domain. Cardiac surgery is among the most complex and risk-sensitive specialties, and the successful initiation of a robotic program there validates the technology's safety and efficacy. It also demonstrates SS Innovations' ability to support clinicians in adopting new techniques, which is essential for driving adoption in other markets.

As the company continues to expand its installed base and procedure volumes, while pursuing regulatory approvals in major markets, it is building a compelling growth narrative. The Sri Lankan program adds to that narrative by illustrating how SS Innovations is helping to democratize access to advanced surgical care. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. For full terms of use and disclaimers, please visit https://IBN.ai/Disclaimer.